Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of Transgene’s virus-based immunotherapies TG6002 and TG1050 in Greater China

information fournie par Boursorama •10/07/2018 à 13:00

Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of Transgene's virus-based immunotherapies TG6002 and TG1050 in Greater China

? Transgene to receive $48 million paid in newly created Tasly Biopharmaceuticals shares
? Deals give Tasly Biopharmaceuticals full control over Greater China development and commercial rights to the oncolytic virus T601 and the therapeutic vaccine T101
? Development of these immunotherapies for the Chinese market will benefit from the significant resources and capabilities of Tasly Biopharmaceuticals

The press release is available on www.trangene.fr